Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non-Current Assets (2016 - 2025)

Enanta Pharmaceuticals' Non-Current Assets history spans 14 years, with the latest figure at $130.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 62.51% year-over-year to $130.8 million; the TTM value through Dec 2025 reached $365.7 million, up 10.12%, while the annual FY2025 figure was $76.4 million, 0.53% down from the prior year.
  • Non-Current Assets reached $130.8 million in Q4 2025 per ENTA's latest filing, up from $76.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $130.8 million in Q4 2025 to a low of $38.2 million in Q4 2023.
  • Average Non-Current Assets over 5 years is $77.2 million, with a median of $74.3 million recorded in 2022.
  • The largest YoY upside for Non-Current Assets was 224.03% in 2021 against a maximum downside of 64.3% in 2021.
  • A 5-year view of Non-Current Assets shows it stood at $113.6 million in 2021, then plummeted by 43.83% to $63.8 million in 2022, then crashed by 40.16% to $38.2 million in 2023, then surged by 110.75% to $80.5 million in 2024, then skyrocketed by 62.51% to $130.8 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Non-Current Assets are $130.8 million (Q4 2025), $76.4 million (Q3 2025), and $78.3 million (Q2 2025).